help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aimaretti, G.
Right arrow Articles by Ghigo, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aimaretti, G.
Right arrow Articles by Ghigo, E.
The Journal of Clinical Endocrinology & Metabolism Vol. 85, No. 10 3693-3699
Copyright © 2000 by The Endocrine Society


Original Studies

Retesting Young Adults with Childhood-Onset Growth Hormone (GH) Deficiency with GH-Releasing-Hormone-Plus-Arginine Test1

G. Aimaretti, C. Baffoni, S. Bellone, L. Di Vito, G. Corneli, E. Arvat, L. Benso, F. Camanni and E. Ghigo

Division of Endocrinology (G.A., C.B., S.B., L.D.V., G.C., E.A., F.C., E.G.), Department of Internal Medicine, University of Turin; and Chair of Auxopathology (L.B.), Department of Pediatrics, University of Turin, 10126 Torino, Italy

Address correspondence and requests for reprints to: Ezio Ghigo, M.D., Divisione di Endocrinologia, Ospedale Molinette, C.so Dogliotti 14, 10126 Torino, Italy. E-mail: ezio.ghigo{at}unito.it

Within an appropriate clinical context, severe GH deficiency (GHD) in adults has to be defined biochemically by provocative testing of GH secretion. Patients with childhood-onset GHD need retesting in late adolescence or young adulthood to verify whether they have to continue recombinant human GH treatment. GHRH + arginine (GHRH+ARG) is the most reliable alternative to the insulin-induced hypoglycemia test (ITT) as a provocative test for the diagnosis of GHD in adulthood, provided that appropriate cut-off limits are assumed (normal limits, 16.5 µg/L as 3rd and 9.0 µg/L as 1st centile). We studied the GH response to a single GHRH (1 µg/kg iv) + ARG (0.5 g/kg iv) test in 62 young patients who had undergone GH replacement in childhood, based on the following diagnosis: 1) organic hypopituitarism with GHD (oGHD) [n = 18: 15 male (M), 3 female (F); age, 26.8 ± 2.2 yr; GH peak < 10 µg/L after two classical tests]; 2) idiopathic isolated GHD (iGHD) [n = 23 (15 M, 8 F); age, 23.0 ± 1.5 yr; GH peak < 10 µg/L after two classical tests]; and 3) GH neurosecretory dysfunction (GHNSD) [n = 21 (10 M, 11 F); age, 25.1 ± 1.6 yr; GH peak > 10 µg/L after classical test but mGHc < 3 µg/L]. The GH responses to GHRH+ARG in these groups were also compared with that recorded in a group of age-matched normal subjects (NS) [n = 48 (20 M, 28 F); age, 27.7 ± 0.8 yr]. Insulin-like growth factor I levels in oGHD subjects (61.5 ± 13.7 µg/L) were lower (P < 0.001) than those in iGHD subjects (117.2 ± 13.1 µg/L); the latter were lower than those in GHNSD subjects (210.2 ± 12.9 µg/L), which, in turn, were similar to those in NS (220.9 ± 7.1 µg/L). The mean GH peak after GHRH+ARG in oGHD (2.8 ± 0.8 µg/L) was lower (P < 0.001) than that in iGHD (18.6 ± 4.7 µg/L), which, in turn, was clearly lower (P < 0.001) than that in GHNSD (31.3 ± 1.6 µg/L). The GH response in GHNSD was lower than that in NS (65.9 ± 5.5 µg/L), but this difference did not attain statistical significance. With respect to the 3rd centile limit of GH response in young adults (i.e. 16.5 µg/L), retesting confirmed GHD in all oGHD, in 65.2% of iGHD, and in none of the GHNSD subjects. With respect to the 1st centile limit of GH response (i.e. 9.0 µg/L), retesting demonstrated severe GHD in 94% oGHD and in 52.1% of iGHD. All oGHD and iGHD with GH peak after GHRH+ARG lower than 9 µg/L had also GH peak lower than 3 µg/L after ITT. In the patients in whom GHD was confirmed by retesting, the mean GH peak after GHRH+ARG was higher than that after ITT (3.4 ± 0.5 vs. 1.9 ± 0.4). In conclusion, given appropriate cut-off limits, GHRH+ARG is as reliable as ITT for retesting patients who had undergone GH treatment in childhood. Among these patients, severe GHD in adulthood is generally confirmed in oGHD, is frequent in iGHD, but never occurs in GHNSD.




This article has been cited by other articles:


Home page
Eur J EndocrinolHome page
V Gasco, G Corneli, G Beccuti, F Prodam, S Rovere, J Bellone, S Grottoli, G Aimaretti, and E Ghigo
Retesting the childhood-onset GH-deficient patient
Eur. J. Endocrinol., December 1, 2008; 159(suppl_1): S45 - S52.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. Misra, M. A. Bredella, P. Tsai, N. Mendes, K. K. Miller, and A. Klibanski
Lower growth hormone and higher cortisol are associated with greater visceral adiposity, intramyocellular lipids, and insulin resistance in overweight girls
Am J Physiol Endocrinol Metab, August 1, 2008; 295(2): E385 - E392.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
G. Corneli, C. Di Somma, F. Prodam, J. Bellone, S. Bellone, V. Gasco, R. Baldelli, S. Rovere, H. J. Schneider, L. Gargantini, et al.
Cut-off limits of the GH response to GHRH plus arginine test and IGF-I levels for the diagnosis of GH deficiency in late adolescents and young adults
Eur. J. Endocrinol., December 1, 2007; 157(6): 701 - 708.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
K. H. Darzy, S. S. Pezzoli, M. O. Thorner, and S. M. Shalet
Cranial Irradiation and Growth Hormone Neurosecretory Dysfunction: A Critical Appraisal
J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1666 - 1672.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Radovick and S. DiVall
Approach to the Growth Hormone-Deficient Child during Transition to Adulthood
J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1195 - 1200.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Colao, C. Di Somma, F. Rota, S. Di Maio, M. Salerno, A. Klain, S. Spiezia, and G. Lombardi
Common Carotid Intima-Media Thickness in Growth Hormone (GH)-Deficient Adolescents: A Prospective Study after GH Withdrawal and Restarting GH Replacement
J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2659 - 2665.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Colao, C. Di Somma, M. Salerno, L. Spinelli, F. Orio, and G. Lombardi
The Cardiovascular Risk of GH-Deficient Adolescents
J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3650 - 3655.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Maghnie, F. Cavigioli, C. Tinelli, M. Autelli, M. Arico, G. Aimaretti, and E. Ghigo
GHRH Plus Arginine in the Diagnosis of Acquired GH Deficiency of Childhood-Onset
J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2740 - 2744.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2000 by The Endocrine Society